BOC Sciences Newly Launches SARS-CoV-2-related Inhibitors for COVID-19 Research

BOC Sciences recently announces to launch a series of SARS-CoV-2-related inhibitors for scientists and researchers who are involved with COVID-19 research.

The world’s leading chemical vendor BOC Sciences recently announces to launch a series of SARS-CoV-2-related inhibitors for scientists and researchers who are involved with COVID-19 research. Through years of effort, this company has long been recognized as a trust-worthy supplier of inhibitors, metabolites, impurities, natural compounds, pharmaceutical excipients, intermediates as well as other research chemicals. The more than 100 inhibitors released earlier month are all in stock and are supposed to facilitate lab research.

SARS-CoV-2 is a positive-sense single-stranded RNA virus (+ssRNA) with round or elliptical particles. Previously six pathogenic human coronaviruses (HCoVs) were already recognized, including SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E. SARS-CoV-2 can cause severe acute respiratory symptoms and transmit in humans via respiratory droplets or contacting.

“The wide spread of COVID-19 has made it an urgent task to find an effective therapy against COVID-19,” commented a senior scientist from BOC Sciences. “To find effective antivirals, a lot of studies are focused on explicating the structure of the coronavirus, in the hope to find a cure in this process. At present, S protein, TMPRSS2, ACE2, RdRp, and Mpro are primary targets. BOC Sciences now offers over 100 SARS-CoV-2-realted inhibitors for pharmaceutical companies or institutes to support their current coronavirus research.”

Inhibitors like Ribociclib (CAS 1211441-98-3), Ceritinib (CAS 1032900-25-6), Alectinib (CAS 1256580-46-7), Dolutegravir (CAS 1051375-16-6), Ibrutinib (CAS 936563-96-1), and Ritonavir (CAS 155213-67-5) have attracted much attention during the coronavirus research. Besides, scientists also find that Lopinavir (CAS 192725-17-0) as a protease inhibitor combined with Ritonavir performs against antiretroviral activity. Remdesivir, a nucleotide analogue, also shows an effective activity against SARS-CoV-2 through inhibiting RdRp.

Because of the strict quality management system, the SARS-CoV-2-related inhibitors at BOC Sciences are well qualified and able to ship out quickly. In addition to the in-stock products, it also provides custom synthesis service of either existing inhibitors or novel inhibitors needed by clients. The volume ranges from small-scale to bulk quantities.

For more information about the SARS-CoV-2-related inhibitors at BOC Sciences, please visit: https://www.bocsci.com/products/sars-cov-2-3055.html. Please be noted that BOC Sciences does NOT sell product to patients because theses inhibitors are mainly for research use.

About BOC Sciences
Aiming to facilitate the biochemical and pharmaceutical research for scientists, BOC Sciences has long been supplying a wide range of chemicals including inhibitors, metabolites, impurities, natural compounds, and pharmaceutical excipients. Meanwhile, it also spares no effort in introducing and offering the most up-to-date strategies and solutions such as medicinal chemistry, drug testing, custom synthesis, analysis/purification, drug formulation, hopefully to shed some light on the industry’s most urgent drug R&D issues.

Contact Info:
Name: Alex Brown
Email: Send Email
Organization: BOC Sciences
Address: 45-16 Ramsey Road, Shirley, NY 11967, USA
Website: https://www.bocsci.com/

Release ID: 88953155